CordenPharma has announced the commissioning of new GMP capacities at its Frankfurt site to manufacture early clinical phase peptide APIs. The investment is still being finalised, but will be fully operational in Q2 and authorised by German authorities in 2H.
International Chemical Investors Group (ICIG), the owner of WeylChem and many other European assets, has acquired two more operations. The acquisition of HCS Group in June followed on from that of Organica Feinchemie in May. Terms were not disclosed in either deal.
CordenPharma has signed a multi-year agreement for the contract manufacture of a large-volume launch peptide at its former Roche facility in Boulder, Colorado. This will begin in 2023 and will potentially be worth about $1 billion, depending on actual production levels required. The customer has not been named and no further details are being disclosed.
Due to the ongoing COVID-19 pandemic and continued uncertainties about international travel, Mack-Brooks Exhibitions has announced the postponement of Chemspec Europe 2021, which was scheduled to take place at Messe Frankfurt on 29-30 September 2021. It will now return to its late spring slot on 31 May-1 June 2022, at the same venue.
Mack-Brooks Exhibitions has announced the postponement of the fine and speciality chemicals trade show, Chemspec Europe 2021 in view of continued uncertainties regarding travel restrictions and event planning during the COVID-19 pandemic. Last year’s show was twice postponed and finally replaced with a digital event.
Chemspec Europe 2021, the 35th in the series, was originally scheduled for 19-20 May at Messe Frankfurt. It will now be a hybrid physical-digital event on 29-30 September, merging the “on-site offer with interactive digital networking opportunities”.
CordenPharma has announced the approval of a long-term expansion initiative “to further increase our flexibility, efficiency and ultimately, cost-effective production” at its solid-phase peptide synthesis (SPPS) in Boulder, Colorado. This follows the installation of an extra-large 3,000L SPPS vessel at the site earlier this year in response to growing demand for peptide APIs.
CordenPharma is to expand non-GMP solid-phase peptide synthesis (SPPS) capacity at its centre of excellence for peptide process development and non-GMP manufacturing at Frankfurt, Germany. This should be complete in Q3 2021. The amount invested has not been disclosed.
The investment will increase lab space by 25% and add a dedicated explosionproof area. The latter will be supported by a tank farm, which, the company said, “will allow for the introduction of regular solvents, as well as compatibility with our green peptide manufacturing”.
